Drug Database
FL

Fluosol-DA (Fluosol)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · Small Molecule · Small Molecule

What is Fluosol-DA?

Fluosol-DA is a small molecule developed by Mitsubishi Tanabe Pharma Corporation. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesFluosol
CompanyMitsubishi Tanabe Pharma Corporation
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

Fluosol-DA is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

Related Research Articles

PubMedbioRxiv : the preprint server for biology2026-07-17

Dopamine Abundance Uncouples Neurodegeneration and Lifespan in a C. elegans Model of Parkinson's Disease.

Willicott Corey W CW, Altman Tyler J TJ, Kimble Logan C LC, Berkowitz Laura A LA et al.

The neuropathology of Parkinson's disease is characterized by α-synuclein (α-syn) aggregation and dopaminergic (DAergic) neurodegeneration. While neuronal loss in C. elegans α-syn-induced neurodegeneration models is temporally age-dependent, prior research indicates it is uncoupled from the organismal aging process. Here we examined transgenic C. elegans expressing human A53T α-syn in DAergic neurons to determine the impact of localized DA metabolism on both neurodegeneration and organismal lifespan. Increasing endogenous DA levels through overexpression of tyrosine hydroxylase (CAT-2) exacerbated A53T-induced DAergic degeneration, whereas DA depletion via Δ cat-2 mutation rescued neuronal survival. By mutating a DA-interaction motif within α-syn, neurodegeneration was rendered insensitive to DA manipulation, thus confirming a structural basis for in vivo toxicity. We identified a DA-α-syn interaction that acts as a common upstream bridge whereby localized stress induces physiological responses in C. elegans . Genetically, this biochemical interaction acts as a pleiotropic trigger driving two compartmentalized responses: localized DAergic neurodegeneration via oxidative stress, and organism-wide, TFEB/ hlh-30 -dependent proteostatic remodeling that extends lifespan. Modulating autophagy, without exacerbating DA-mediated oxidative stress, represents a promising strategy to preserve adaptive systemic remodeling while limiting targeted neuronal damage.

PubMedbioRxiv : the preprint server for biology2026-07-17

Striatal cholinergic and dopaminergic driven astrocyte Ca 2+ activity is disrupted in Parkinsonian mice.

Evans Wesley R WR, Wells Hunter G HG, Jacob Cynthia C, Vellore Angelica A et al.

Brain neuromodulatory systems exert powerful effects on local neuronal circuit function and behavior. In addition to classical actions directly on neurons, growing evidence indicates that neuromodulators also recruit Ca 2+ -dependent astrocyte mechanisms to regulate synaptic plasticity and network function. The dorsal striatum integrates cortical and thalamic inputs under strong dopamine (DA) and acetylcholine (ACh) neuromodulatory control. To what extent the circuit and behavioral effects of striatal ACh and DA depend on astrocyte Ca 2+ activity remains unclear. We show that locomotion elicits robust DA, ACh, and astrocyte Ca 2+ activity in the dorsolateral striatum (DLS). DA and ACh release exhibits a negative correlation on a fast time scale but shows a positive correlation during continuous locomotion as slower astrocyte Ca 2+ activity builds. Higher ACh and DA release is associated with higher astrocyte events, suggesting that both neurotransmitters drive astrocyte activity. In agreement, pharmacological blockade of muscarinic ACh or D1/D2 DA receptors decreases locomotion-evoked astrocyte Ca 2+ . Closed-loop optogenetic inhibition of striatal cholinergic interneurons (CINs) during locomotion reduces astrocyte Ca 2+ activity, demonstrating a causal contribution of ACh release to astrocyte activity. Locomotion related ACh release was severely compromised in a mouse model of Parkinson's disease (PD), with the dual loss of DA and ACh attenuating astrocyte Ca 2+ activity. Facilitating astrocyte cholinergic signaling via chemogenetics improved both calcium activity and motor deficits in our recent work. Thus, the pathophysiology of PD in part involves attenuated astrocyte Ca 2+ signaling, placing these non-neuronal cells as a prime underexplored therapeutic target for PD.

PubMedActa biomaterialia2026-07-17

A biomimetic supramolecular hydrogel enabling sequential dual-agent release reprograms the inflammatory microenvironment for sciatic nerve regeneration.

Zhu Ziming Z, Huo Huilin H, Liu Xiaofei X, Zhang Jinpeng J et al.

Peripheral nerve injury (PNI) repair is fundamentally hindered by a dysregulated inflammatory microenvironment and insufficient bioactive components. Conventional hydrogels fail to concurrently integrate dynamic responsiveness, neural biomimicry, and inflammation regulation. Herein, we engineered a biomimetic supramolecular hydrogel capable of reprogramming the immune microenvironment. This hydrogel was constructed through the reversible self-assembly of carboxymethyl chitosan (CM-CTS) and oxidized chondroitin sulfate (OCS), enabling the sequential release of a vascular endothelial growth factor mimetic peptide (QK) and dopamine (DA). The hydrogel, designated QK@CM-CTS/OCS-DA, exhibited critical biomaterial properties for neural applications: injectability for minimally invasive delivery, rapid self-healing capability, robust structural stability under dynamic conditions, appropriate mechanical strength matching soft neural tissue, and favorable cytocompatibility. Moreover, in vivo implantation of the hydrogel elicited no discernible inflammatory response, and it underwent near-complete degradation within 6 weeks. Furthermore, the QK@CM-CTS/OCS-DA hydrogel actively reprogrammed the injury site: the initial burst release of the QK peptide potently modulated macrophage polarization toward an anti-inflammatory M2 phenotype and drove early angiogenesis, while the subsequent sustained release of dopamine synergized with the CM-CTS/OCS matrix to promote Schwann cell migration, axonal extension, and myelination. Crucially, the QK@CM-CTS/OCS-DA hydrogel repaired the injured rat sciatic nerve, attenuated gastrocnemius atrophy, and promoted remyelination, restored the conduction function and motor function. While modulating inflammation and immune responses, the QK@CM-CTS/OCS-DA hydrogel also effectively enhanced energy supply, creating favorable microenvironment for peripheral nerve regeneration. Consequently, this study developed a QK@CM-CTS/OCS-DA biomimetic supramolecular hydrogel with sequential delivery functionality and demonstrated its therapeutic potential in PNI repair. STATEMENT OF SIGNIFICANCE: Peripheral nerve injuries are challenging to treat due to harmful inflammation and insufficient bioactive components. Conventional hydrogels fail to concurrently integrate dynamic responsiveness, neural biomimicry, and inflammatory microenvironment reprogramming. Herein, the CM-CTS/OCS matrix employed endows the hydrogel with injectability, self-healing capability, and appropriate mechanical strength, enabling minimally invasive implantation and adaptation to irregular nerve defect cavities while maintaining structural integrity. Through the sequential release of QK peptide and dopamine, the QK@CM-CTS/OCS-DA hydrogel reduces oxidative stress, attenuates early inflammation, guides Schwann cell migration, accelerates axon regrowth, and enhances myelin formation. This study has developed a mechanism-driven biomimetic supramolecular hydrogel, which combines dynamic material design with complex biological effects, providing active substances and an appropriate regenerative microenvironment for peripheral nerve regeneration.

PubMedProteomics. Clinical applications2026-07-17

Distinct Functional Signatures of Human Olfactory and Respiratory Mucus Revealed by Proteomics Combined With Machine Learning.

Topalian Romain R, Hernandez Anna Kristina AK, Lantzsch Karoline K, Hubel Philipp P et al.

The nasal cavity includestwo distinct epithelial regions: olfactory and respiratory which fulfilldifferent roles. Despite their differences, their mucus composition, however, is yet not well elucidated. To analyze themucosal secretome, samples from the human olfactory mucus (OM) and respiratorymucus (RM) were collected in a volunteer study with 25 normosmic individualsand analyzed using label-free quantitative proteomics (LFQ), supervised machinelearning (Partial Least Squares Discriminant Analysis, PLS-DA), functionalenrichment via Gene Ontology (GO) and pathway analyses at Reactome database. A total of 1,780high-confidence proteins were quantified across 50 samples. The optimizedPLS-DA model achieved robust discrimination between OM and RM (AUC = 0.93 ±0.04), identifying distinct molecular signatures. Cross-validation across GO,Reactome, and PLS-DA macro-category analyses confirmed the robustness andbiological coherence of these findings. Overall, this study defines twocomplementary mucosal ecosystems: a dynamic olfactory mucus optimized for highmitochondrial activity, (non-motile) ciliary renewal, and autophagy, and animmune-active respiratory mucus specialized in host defense, providing acomprehensive molecular framework of nasal regional specialization.

PubMedAnnals of surgical oncology2026-07-17

A Prospective, Multicenter Randomized Controlled Trial (RCT) of the da Vinci SP® Surgical System versus Open Surgery in Nipple-Sparing Mastectomy (NSM) Procedures for Patients with Breast Cancer.

Kopkash Katherine K, Piltin Mara M, Jakub James J, Javid Sara S et al.

This prospective randomized trial evaluated the safety and effectiveness of robotic-assisted nipple-sparing mastectomy (rNSM) using the da Vinci Single Port (SP)® compared with open NSM in women with early stage breast cancer. This Food and Drug Administration (FDA) investigational device exemption (IDE)-approved, two-arm, multicenter randomized controlled trial (RCT) randomized eligible women (clinical Tis-T2, N0) 1:1 to rNSM or open NSM with immediate implant-based reconstruction. Operations were performed at 14 US sites by 23 surgeons. Primary endpoints included conversion to open surgery, adverse events at 42 days, and positive surgical margin (PSM) rates. Secondary outcomes included operative time, estimated blood loss, nipple-areolar complex (NAC) and skin flap viability, final pathology, and patient-reported outcomes (BREAST-Q). Overall, 74 patients completed surgery, totaling 65 rNSM (38 therapeutic, 27 prophylactic) and 66 open NSM (38 therapeutic, 28 prophylactic). Operative time was longer for rNSM (141.6 versus 83.9 min) with no conversions to open surgery. Serious adverse events (SAEs) occurred in three rNSM and eight open NSM patients, with no device-related SAEs reported. NAC preservation at 42 days was 100% for rNSM and 98.5% for open NSM. PSM rates were identical (six patients each). Higher BREAST-Q scores favored rNSM in multiple domains. These results demonstrate that da Vinci SP® rNSM is feasible and has a safety profile comparable to open NSM for early stage breast cancer, with similar margin status and postoperative complications. Although SAEs and patient-reported outcomes were more favorable with rNSM, these differences were not statistically significant. rNSM was associated with longer operative times, which may in part reflect early experience with the technique.

PubMedBiomedical chromatography : BMC2026-07-17

LC-MS/MS Method for Quantifying the Alterations of Four Neurotransmitters in Plasma From Insomnia Patients Treated With Zhibai Anshen Oral Liquid.

Xu Jingjie J, Chu Yaqin Y, Levin Timothy T, Li Huanchen H et al.

Zhibai Anshen (ZbAs) oral liquid is employed to alleviate insomnia. However, the neurotransmitters in this treatment are insufficiently investigated. This study aimed to establish a method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for determination of 5-hydroxytryptamine (5-HT), dopamine (DA), epinephrine (E), and norepinephrine (NE) in the plasma of patients treated with ZbAs. Plasma samples were processed by protein precipitation with acetonitrile containing internal standard linezolid. Insomnia patients were enrolled and treated with ZbAs, and the plasma samples were collected at baseline and end of treatment. The Pittsburgh Sleep Quality Index (PSQI) was retrieved and the concentrations of neurotransmitters were quantified. The method was successfully developed and validated. It was successfully applied to analyzing plasma samples from 51 patients, revealing a significantly increased level of 5-HT and obviously decreased levels of NE and DA after treatment, while the E kept steady against ZbAs. The PSQI significantly decreased after ZbAs treatment (21.63 ± 6.94 vs. 16.44 ± 7.17, p = 0.0006). A rapid, simple, and sensitive LC-MS/MS method for the determination of four neurotransmitters was established. ZbAs showed satisfying efficacy in treating insomnia, accompanied by obvious alterations of three neurotransmitters, which may be regarded as indicators for efficacy assessment of ZbAs.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Fluosol-DA